EIR Biopharma Files for IPO to Fund Eye Disease Pipeline

The proposed offering could raise up to $18.75 million at the top end of the price range. While the company has not yet disclosed its intended ticker symbol or exchange, the filing signals an aggressive push to capitalize on its development-stage pipeline.

Capital Strategy for EIR-1003

Proceeds from the IPO are earmarked primarily for the preclinical and clinical development of EIR-1003, the company's flagship therapeutic candidate. Beyond direct drug development, the firm plans to allocate the new capital toward several operational areas:

• Ongoing research and development activities
• Working capital requirements
• General corporate purposes

Kingswood Capital has been granted an 18-month right of first refusal to act as the lead manager and bookrunner for the transaction. The move comes as early-stage biotechs continue to seek public funding to navigate the capital-intensive regulatory hurdles associated with clinical trials.